Business Description
SELLAS Life Sciences Group Inc
NAICS : 325412
SIC : 2834
ISIN : US81642T1007
Description
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
Financial Strength
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 13.22 | |||||
Equity-to-Asset | 0.19 | |||||
Debt-to-Equity | 0.24 | |||||
Debt-to-EBITDA | -0.02 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 13.8 | |||||
3-Year EPS without NRI Growth Rate | 14.4 | |||||
3-Year FCF Growth Rate | -0.6 | |||||
Future 3-5Y EPS without NRI Growth Rate | 31.39 |
Momentum Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 59 | |||||
9-Day RSI | 58.71 | |||||
14-Day RSI | 56.84 | |||||
6-1 Month Momentum % | 31.77 | |||||
12-1 Month Momentum % | -21.15 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.02 | |||||
Quick Ratio | 1.02 | |||||
Cash Ratio | 0.76 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -31.1 | |||||
Shareholder Yield % | -35.18 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -3054.73 | |||||
ROA % | -237.76 | |||||
ROIC % | -695.72 | |||||
ROC (Joel Greenblatt) % | -4943.75 | |||||
ROCE % | -2468.02 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 26.4 | |||||
Price-to-Tangible-Book | 77.65 | |||||
EV-to-EBIT | -2.2 | |||||
EV-to-EBITDA | -2.2 | |||||
EV-to-Forward-Revenue | 2.2 | |||||
EV-to-FCF | -2.38 | |||||
Earnings Yield (Greenblatt) % | -45.45 | |||||
FCF Yield % | -37.87 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
SELLAS Life Sciences Group Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | |||
EPS (TTM) (€) | -0.852 | ||
Beta | 1.77 | ||
Volatility % | 89.24 | ||
14-Day RSI | 56.84 | ||
14-Day ATR (€) | 0.038071 | ||
20-Day SMA (€) | 1.1037 | ||
12-1 Month Momentum % | -21.15 | ||
52-Week Range (€) | 0.45 - 1.768 | ||
Shares Outstanding (Mil) | 64.33 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
SELLAS Life Sciences Group Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
SELLAS Life Sciences Group Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
SELLAS Life Sciences Group Inc Frequently Asked Questions
What is SELLAS Life Sciences Group Inc(FRA:RXK3)'s stock price today?
The current price of FRA:RXK3 is €1.17. The 52 week high of FRA:RXK3 is €1.77 and 52 week low is €0.45.
When is next earnings date of SELLAS Life Sciences Group Inc(FRA:RXK3)?
The next earnings date of SELLAS Life Sciences Group Inc(FRA:RXK3) is 2024-11-08 Est..
Does SELLAS Life Sciences Group Inc(FRA:RXK3) pay dividends? If so, how much?
SELLAS Life Sciences Group Inc(FRA:RXK3) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |